一元线性回归算法在生物化学分析仪上的应用研究

目的：实现一种应用于生物化学分析仪的定量分析方法。方法：利用一元一次线性回归模型，结合标准曲线来计算待测样本的浓度值。结果：经过验证和临床测试，该算法可满足性能要求，且有效可行。结论：该方法能很好地满足临床应用，并能扩展到工业检测、食品安全等领域。     

两种尿沉渣分析仪在临床上的应用评价

目的对Diasys R／S2003和普利生尿沉渣分析系统进行性能及临床应用的评估。方法分别对两台尿沉渣仪与牛鲍氏计数板法进行可比性试验，并对两仪器作准确性、重复性、线性检测；对Diasys进行携带污染率检查。结果Diasys R／S2003和普利生均与牛鲍氏计数板法显示相关（r〉r0．01）且有非常显著性意义（P〈0．01）；准确率分别为124．2％和95．8％；重复性低值CV％分别为6．5％和3．6％，高值CV％分别为6．2％和3．7％；且均显示良好线性；而Diasys的携带污染率为0．14％。结论两台仪器均符合NCCLS尿沉渣定量分析标准，检测结果与临床相符，具有准确性好、精密度高、操作简便、污染少、成本低等优点，因此两者都是目前比较理想的尿沉渣分析仪。     

Successful Treatment of Erdheim-Chester Disease With Coronary Artery Involvement

Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis and inflammatory myeloid neoplasm with poor prognosis. Symmetric long bone osteosclerosis occurs in nearly all patients, but other organs are often involved. Coronary artery involvement is rare, but was encountered in a patient who experienced angina. Radiologic presentation and histologic findings were consistent with diagnosis of ECD. A soft-tissue mass was found surrounding the right atrium, ascending aorta, and all branches of coronary artery. Interferon-alfa treatment was successful. In conclusion, we recommend coronary artery computed tomography angiography for cardiovascular evaluation of ECD and interferon-alfa to treat ECD.     

XC-A30A型全自动血沉分析仪的应用评价

目的探讨XC-A30A型全自动血沉分析仪测定红细胞沉降率(ESR)的重复性、准确性及影响因素。方法抽取高、中、低三组血沉值共27份进行重复性试验,对做血沉检查的198例患者,采用两法测定,以统计学方法分析仪器法的准确性,抽取10例贫血患者标本(压积<0.30)和10例压积正常且魏氏法ESR值在21～100 mm/h的标本对照,分析贫血标本用仪器测定的可行性。结果重复性:除1例(CV为16.1%)外,其余26例CV均<5%。准确性:ESR值在2～100 mm/h各组差异无统计学意义(P>0.05),但ESR值>100 mm/h者两组差异有统计学意义(P<0.05)。贫血标本采用两法测定的差值与对照组比较差异有统计学意义(P<0.05)。结论 XC-A30A型全自动血沉分析仪具有良好的重复性,准确性较高,贫血标本用该仪器测定准确性也较高,适合医院快速准确的报告血沉结果。但对于ESR>100 mm/h时建议用手工法复查。     

Assessment of light transmission aggregometry on the routine coagulation analyzer Sysmex CS-2500 using CE-marked agonists from Hyphen Biomed

Light transmission aggregometry (LTA) is still considered as the “gold standard” for platelet function assessment but, as acompletely manual technology, it is labour intensive. This challenge can be overcome by performing platelet aggregometry in anautomated method on a routine coagulation analyzer. We aimed to compare and correlate results obtained from a traditional manual LTA solution realized in our Reference Center with an optimized automated system using CE-marked agonist reagents. Platelet rich plasma from patients with suspected platelet disorders, von Willebrand disease or antiplatelet therapy have been assessed using a wide range of agonist concentrations. Results were expressed as Maximal Platelet Aggregation and correlation was analyzed using the Passing and Bablok regression test. Platelet aggregometry studies were performed in 49 samples. Maximal aggregation response with ADP (0.5-10 μM), collagen (2 mg/μL), ristocetin (1.2 mg/mL) and arachidonic acid (1 mM) agonists showed significant correlation between the two aggregometers (p< .001). We observed a more variable response using lowconcentrations of ADP (≤5 μM). Moreover, we also noted discrepancies with the low dose of ristocetin, showing excessive paradoxical agglutination with the CS-2500, suggesting that a lower ristocetin dose should be used with this system. These data show that CS-2500 has the advantages of a walk-away technology and the use of CE-marked reagents also permit the possibility of an easier certification.     

全自动尿沉渣分析仪Sysmex UF-1000i的性能评价

目的评价Sysmex UF-1000i全自动尿沉渣分析仪(简称Sysmex UF-1000i)的性能,以探讨其是否符合临床要求。方法按照实验室ISO15189要求,检测白细胞(WBC)计数、红细胞(RBC)计数、上皮细胞(EC)计数、管型(CAST)计数及细菌(BACT)计数5项指标的批内精密度、批间精密度、携带污染率、线性范围、准确度并验证生物参考区间。结果 Sysmex UF-1000i对白细胞(WBC)、红细胞(RBC)、上皮细胞(EC)、管型(CAST)、细菌(BACT)的低值质控批内精密度、高值质控批内精密度、低值质控批间精密度、高值质控批间精密度、低值质控准确度、高值质控准确度,以及RBC、BACT的携带污染率(分别为0.02%和0.00%)均符合厂家要求。WBC、RBC、BACT的线性相关系数r2分别为0.999 4,0.999 8,0.999 8,r2均不低于0.95,线性良好。结论 UF-1000i各项性能均符合ISO15189对性能评价的要求,可应用于临床尿液沉渣的检验。     

340nm波长酶标免疫分析仪的实现

本文详细介绍了支持340hm波长酶标免疫分析仪工作原理和电路结构的设计与实现。通过准确性测试、线性度测试和重复性测试，证实该酶标免疫分析仪实现支持340nto波长的测试，能很好地满足临床某些科研测试的需求，是高端酶标的一个重要体现。实验还证明，采用一定的软硬件技术，配合光路的设计，能使340nm波长完全达到国家对酶标免疫分析仪的性能标准。     

Mitochondrial compromise in 3‐year old patas monkeys exposed in utero to human‐equivalent antiretroviral therapies

Antiretroviral (ARV) drug therapy, given during pregnancy for prevention of mother‐to‐child transmission of human immunodeficiency virus 1 (HIV‐1), induces fetal mitochondrial dysfunction in some children. However, the persistence/reversibility of that dysfunction is unclear. Here we have followed Erythrocebus patas (patas) monkey offspring for up to 3 years of age (similar in development to a 15‐year old human) after exposure of the dams to human‐equivalent in utero ARV exposure protocols. Pregnant patas dams (3–5/exposure group) were given ARV drug combinations that included zidovudine (AZT)/lamivudine (3TC)/abacavir (ABC), or AZT/3TC/nevirapine (NVP), for the last 10 weeks (50%) of gestation. Infants kept for 1 and 3 years also received drug for the first 6 weeks of life. In offpsring at birth, 1 and 3 years of age mitochondrial morphology, examined by electron microscopy (EM), was compromised compared to the unexposed controls. Mitochondrial DNA (mtDNA), measured by hybrid capture chemiluminescence assay (HCCA) was depleted in hearts of patas exposed to AZT/3TC/NVP at all ages (P < 0.05), but not in those exposed to AZT/3TC/ABC at any age. Compared to unexposed controls, mitochondrial reserve capacity oxygen consumption rate (OCR by Seahorse) in cultured bone marrow mesenchymal fibroblasts from 3‐year‐old patas offspring was ～50% reduced in AZT/3TC/ABC‐exposed patas (P < 0.01), but not in AZT/3TC/NVP‐exposed patas. Overall the data show that 3‐year‐old patas sustain persistent mitochondrial dysfunction as a result of perinatal ARV drug exposure. Environ. Mol. Mutagen. 57:526–534, 2016. © 2016 Wiley Periodicals, Inc.